Bruker (BRKR) Q2 FY26 earnings call

Bruker returned to organic revenue growth in Q2 FY26, driven by strong demand in deep tech and biopharma, despite continued weakness in U.S. academic markets and China revenue declines. The company delivered significant margin expansion and EPS growth, benefiting from cost reduction initiatives and tariff refunds. Management expects continued profitability improvements and double-digit EPS growth in FY26 and FY27, supported by a strong order book and a new operating structure.